Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Mylan Inc    MYL   US6285301072


News SummaryMost relevantAll newsSector news 

Mylan Inc. : Mylan Launches First Generic Version of Doryx® 150 mg

04/30/2012 | 02:20pm US/Eastern

PITTSBURGH, April 30, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg, following a favorable decision by the U.S. District Court for the District of New Jersey in a patent infringement lawsuit brought by Warner Chilcott. The Court held, after trial, that Mylan's product does not infringe the subject patent. Mylan is shipping product immediately.

Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg is the generic version of Mayne Pharma's Doryx(®) 150 mg product (marketed by Warner Chilcott), and is a tetracycline-class antimicrobial.

Doxycycline Hyclate DR Tablets, 150 mg, had U.S. sales of approximately $264.1 million for the 12 months ending Dec. 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit For more information about generic drugs, please visit

SOURCE Mylan Inc.

React to this article
Latest news on MYLAN INC
05:50aDJMARKET SNAPSHOT : U.S. Stocks: Futures Retreat After Nasdaq Breaks Above 5,000
03/02 MYLAN : Management's Discussion and Analysis of Financial Condition And Results ..
03/02DJMylan Posts Higher Profit and Sales
03/02 MYLAN : Files Annual Report on Form 10-K for Year Ended Dec. 31, 2014
03/02DJMARKET SNAPSHOT : U.S. Stocks Close At Records; Nasdaq Ends Above 5,000
03/02 MYLAN : tops 4Q profit forecasts before move overseas
03/02 MYLAN : Results of Operations and Financial Condition, Financial Statements and ..
03/02DJMARKET SNAPSHOT : U.S. Stocks: Futures Falter Ahead Of Data Deluge
03/02DJMARKET SNAPSHOT : U.S. Stocks: Futures Edge Higher Ahead Of Data Deluge
03/02DJMARKET SNAPSHOT : U.S. Stocks: Futures Climb Ahead Of Data Deluge
Dynamic quotes